Breast cancer prognostic test Digistain available to selected UK private patients with reimbursement from Bupa, WPA and Healix
November 27, 2024
Professor Samuel Haryono from the Siloam Group Indonesia visits Digistain research lab at Imperial College London
January 29, 2025
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024.
The first abstract presented data from Charing Cross Hospital on Digistain and metastasis-free survival.
The second abstract focused on assessing Digistain’s robustness by assessing its performance against variations in tissue fixation time, reporting its performance across a range of fixation times.
We continue to work to provide recurrence-risk information to clinicians and patients.
https://sabcs.org/Call-for-Abstracts-2024
